Resultats globals: 14 registres trobats en 0.01 segons.
Articles, 14 registres trobats
Articles 14 registres trobats  1 - 10següent  anar al registre:
1.
9 p, 1.6 MB Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab / Trilla-Fuertes, Lucía (Biomedica Molecular Medicine (Madrid)) ; Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; García-Carbonero, Rocío (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ; Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ; G-Pastrián, Laura (Hospital Universitario La Paz (Madrid)) ; Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ; Peña, Cristina (Hospital Universitario La Paz (Madrid)) ; López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco) ; Llorens, Carlos (Biotechvana SL (Madrid)) ; Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ; Conill, Carles (Hospital Clínic i Provincial de Barcelona) ; Heredia-Soto, Victoria (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Fresno Vara, Juan Ángel (Centro de Investigación Biomédica en Red de Cáncer) ; Feliu, Jaime (Universidad Autónoma de Madrid) ; Universitat Autònoma de Barcelona
Squamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80-90% of tumors). [...]
2021 - 10.1038/s41598-021-86966-w
Scientific reports (Nature Publishing Group), Vol. 11 (april 2021)  
2.
9 p, 1.3 MB Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set / Grothey, Axel (Mayo Clinic) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Bodoky, Gyorgy (St László Hospital (Hongria)) ; Ciuleanu, Tudor (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ; García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Muro, Kei (Aichi Cancer Center Hospital) ; Mytelka, Daniel S (Formerly of Eli Lilly and Company) ; Li, Li (Eli Lilly and Company) ; Lipkovich, Olga (Eli Lilly and Company) ; Hsu, Yanzhi (Eli Lilly and Company) ; Sashegyi, Andreas (Eli Lilly and Company) ; Ferry, David (Eli Lilly and Company) ; Nasroulah, Federico (Eli Lilly Argentina) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)  
3.
16 p, 1003.6 KB Update of the recommendations for the determination of biomarkers in colorectal carcinoma : National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology / García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; García-Foncillas, Jesús (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Pérez-Segura, Pedro (Hospital Clínico San Carlos (Madrid)) ; Salazar, R. (Centro de Investigación Biomédica en Red de Cáncer) ; Vera, Ruth (Complejo Hospitalario de Navarra) ; Ramón y Cajal, S. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Hernández-Losa, J. (Hospital Universitari Vall d'Hebron) ; Landolfi, S. (Vall d'Hebron Institut d'Oncologia) ; Musulén, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ; Navarro, S. (Hospital Clínic Universitari (València)) ; Universitat Autònoma de Barcelona
In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica-SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica-SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. [...]
2020 - 10.1007/s12094-020-02357-z
Clinical & Translational Oncology, Vol. 22 (may 2020) , p. 1976-1991  
4.
8 p, 712.6 KB Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study / Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Portnoy, D C (The West Clinic, Memphis, USA) ; Obermannová, R (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ; Bodoky, G (St László Hospital (Hongria)) ; Prausová, J (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, T (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Cohn, A L (Rocky Mountain Cancer Center, LLP, Denver, USA) ; Van Cutsem, E (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Yamazaki, K (Shizuoka Cancer Center, Shizuoka, Japan) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ; Muro, K (Aichi Cancer Center Hospital) ; Kim, T W (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ; Yamaguchi, K (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ; Grothey, A (Mayo Clinic, Phoenix, USA) ; O'Connor, J (Instituto Alexander Fleming (Buenos Aires, Argentina)) ; Taieb, J (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ; Wijayawardana, S R (Eli Lilly and Company, Indianapolis, USA) ; Hozak, R R (Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F (Eli Lilly and Company, Buenos Aires, Argentina) ; Tabernero, J (Universitat Autònoma de Barcelona. Departament de Medicina) ; Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131  
5.
7 p, 1.3 MB Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer / Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Pezet, Denis (Centre Hospitalier Universitaire) ; Deplanque, Gael (Hôpital Riviera-Chablais) ; Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ; Trojan, Jorg (Goethe University Medical Center) ; Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ; Kozloff, Mark (Ingalls Memorial Hospital) ; Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Smith, Claire (formerly of Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ; Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ; Blunt, Al (Advaxis, Inc) ; Benhadji, Karim A. (Eli Lilly and Company) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214  
6.
8 p, 1.4 MB Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma / Trilla-Fuertes, Lucía (Biomedica Molecular Medicine SL, C/Faraday 7, 28049, Madrid, Spain) ; Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ; Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; G-Pastrián, Laura (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ; Peña, Cristina (Hospital Universitario La Paz (Madrid)) ; López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Prado-Vázquez, Guillermo (Biomedica Molecular Medicine SL, C/Faraday 7, 28049, Madrid, Spain) ; López-Camacho, Elena (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Zapater-Moros, Andrea (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Heredia Soto, Victoria (Hospital Universitario La Paz (Madrid)) ; Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ; Conill, Carles (Hospital Clínic i Provincial de Barcelona) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Heath, Karen E. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ; Llorens, Carlos (Biotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ; Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Feliu, Jaime (Universidad Autónoma de Madrid) ; Vara, Juan Ángel Fresno (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the standard of care, with no therapeutic advances achieved over the past three decades. Thus, a deeper molecular characterization of this disease is still necessary. [...]
2020 - 10.1016/j.tranon.2020.100778
Translational Oncology, Vol. 13 (may 2020)  
7.
8 p, 518.2 KB Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) / Solis-Hernandez, Mª Pilar (Hospital Universitario Central de Asturias) ; Fernandez del Valle, Ana (Hospital Universitario Central de Asturias. Radiology Department) ; Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Custodio, Ana (Hospital Universitario La Paz (Madrid)) ; Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Alonso Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ; Nuñez-Valdovino, Bárbara (Hospital Clinico Universidad de Chile (Santiago de Xile, Xile)) ; Sanchez Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia)) ; Matos, Ignacio (Hospital Universitari Vall d'Hebron) ; Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ; Lopez, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Viudez, Antonio (Complejo Hospitalario de Navarra) ; Izquierdo, Marta (Hospital Universitario Central de Asturias) ; Calvo-Temprano, David (Hospital Universitario Central de Asturias) ; Grande, Enrique (MD Anderson Cancer Center) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ; Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias) ; Universitat Autònoma de Barcelona ; Vall d'Hebron Institut d'Oncologiagia
The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. [...]
2019 - 10.1038/s41416-019-0558-7
British Journal of Cancer, Vol. 121 (september 2019) , p. 537-544  
8.
11 p, 939.2 KB Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog : The GETNE-TRASGU Study / Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ; Jiménez-Fonseca, Paula (Hospital Universitario Central de Asturias) ; Lamarca, Ángela (The Christie NHS Foundation Trust, Manchester) ; Barriuso, Jorge (University of Manchester) ; Castaño, Ángel (Hospital Universitario de Fuenlabrada ( Madrid)) ; Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ; Riesco-Martínez, María del Carmen (Hospital Universitario 12 de Octubre (Madrid)) ; Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ; Custodio, Ana (Hospital Universitario La Paz (Madrid)) ; Sánchez Cánovas, Manuel (Hospital Universitario Morales Meseguer, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria) ; Hernando Cubero, Jorge (Vall d'Hebron Institut d'Oncologia) ; López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Lacasta, Adelaida (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ; Fernández Montes, Ana (Complejo Hospitalario Universitario de Ourense) ; Marazuela, Mónica (Hospital Universitario de la Princesa (Madrid)) ; Crespo, Guillermo (Complejo Asistencial Universitario de Burgos) ; Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Diaz, José Ángel (Hospital Clínico San Carlos (Madrid)) ; Feliciangeli, Eduardo (Hospital General Universitario Santa Lucía (Cartagena, Múrcia)) ; Gallego, Javier (Hospital General Universitario de Elche) ; Llanos, Marta (Hospital Universitario de Canarias (La Laguna)) ; Segura, Ángel (Hospital Universitari i Politècnic La Fe de València) ; Vilardell, Felip (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Percovich, Juan Carlos (Hospital General Universitario Gregorio Marañón) ; Grande, Enrique (MD Anderson Cancer Center Madrid) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ; Valle, Juan W. (University of Manchester, Manchester) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. [...]
2019 - 10.1200/JCO.19.00980
Journal of Clinical Oncology, Vol. 37 (august 2019) , p. 2571-2580  
9.
12 p, 182.8 KB Economics of gastroenteropancreatic neuroendocrine tumors : a systematic review / Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ; Díaz, Ángel (Hospital Universitario Clínico SanCarlos) ; López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Munarriz, Javier (Consorci Hospitalari Provincial de Castelló) ; Reina, Juan-José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Vera, Ruth (Complejo Hospitalario de Navarra) ; Bernárdez, Beatriz (Complejo Hospitalario Universitario de Santiago de Compostela) ; Aller, Javier (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; García-Carbonero, Rocío ; Jimenez Fonseca, Paula ; Trapero-Bertran, Marta (Universitat Internacional de Catalunya) ; Universitat Autònoma de Barcelona
Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. [...]
2019 - 10.1177/2042018819828217
Therapeutic Advances in Endocrinology and Metabolism, Vol. 10 (february 2019)  
10.
8 p, 500.4 KB Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer / Siena, S (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ; Sartore-Bianchi, A (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ; García-Carbonero, Rocío (Universidad Complutense) ; Karthaus, M (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ; Smith, D (Bordeaux University Hospital (França)) ; Tabernero, J (Universitat Autònoma de Barcelona) ; Van Cutsem, E (KU Leuven, Leuven, Belgium) ; Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ; Boedigheimer, M (Amgen Inc., Thousand Oaks, CA, USA) ; Ang, A (Amgen Inc., Thousand Oaks, CA, USA) ; Twomey, B (Amgen Inc., Thousand Oaks, CA, USA) ; Bach, B A (Amgen Inc., Thousand Oaks, CA, USA) ; Jung, A S (Amgen Inc., Thousand Oaks, CA, USA) ; Bardelli, A (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 - 10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126  

Articles : 14 registres trobats   1 - 10següent  anar al registre:
Vegeu també: autors amb noms similars
5 Garcia-Carbonero, R.
13 Garcia-Carbonero, Rocio
5 García-Carbonero, R.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.